Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $6.00 +3.45%
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.2 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
For earnings history and earnings-related data on Vanda Pharmaceuticals, Inc. (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- MP Materials seen largely insulated after China export-control move
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
